Sign inJoin waitlistJoin the waitlist

Neeraj Agarwal

, Professor, Division of Oncology · Univ of Utah Sch of Med

Credentials: · · ·

History

Univ of Utah Sch of Med
Present
Univ of Utah Sch of Med
Present

Hematology and Medical Oncology
Huntsman Cancer Institute & Hospital
1998–2001
University of Iowa
1995–1998
All India Institute of Medical Sciences Assam Medical College
1991–1995

Research

Olaparib for Metastatic Castration-Resistant Prostate Cancer
New England Journal of Medicine · 2020 · 1,879 citations
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a…
The Lancet Oncology · 2014 · 1,245 citations
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
New England Journal of Medicine · 2019 · 1,244 citations

Sumanta Pal
124 papers
Umang Swami
109 papers · 14 as a fellow
BM
Benjamin Maughan
77 papers · 7 as a resident
Toni Choueiri
67 papers
Nicolas Sayegh
61 papers · 43 as a resident
Georges Gebrael
55 papers · 45 as a resident
UV
Ulka Vaishampayan
48 papers
Andrew Hahn
46 papers · 43 as a resident
GS
Guru Sonpavde
45 papers
Rana McKay
41 papers · 20 as a resident
Maha Hussain
37 papers
Nishita Tripathi
37 papers · 26 as a resident

Grants

Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression: A Double-Blind Randomized Controlled Trial
National Cancer Institute · R01
PI · $2.7M · Utah State Higher Education System--University of Utah
2023–2028
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $269.5K · Utah State Higher Education System--University of Utah
1997–2027

Clinical trials

Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Principal investigator · Completed · Phase 1
University of Utah
2018–2021
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
Principal investigator · Completed · Phase 2
University of Utah
2013–2018
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Principal investigator · Completed · Phase 3
SWOG Cancer Research Network
2013–2025
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Site PI · Recruiting · Phase 1, Phase 2
Novartis Pharmaceuticals
2026–2032